news
New machine learning model could encode words to kill cancer cells
US researchers, using new machine learning techniques have developed a virtual molecular library of “words” that encode commands to kill cancer cells.
List view / Grid view
Chimeric Antigen Receptors (CARs)
article
Keeping T cells strong and improving cancer immunotherapy
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
news
Novel CAR T screens identify most effective cancer immunotherapy cells
Researchers have developed a new method for comparing CAR T cells, each with slightly different molecular features, to determine which is most effective and long-lasting against cancer.
news
Ground-breaking 3D bioprinted tumours aid immunotherapy research
A team of scientists have 3D bioprinted breast cancer tumours and treated them in a new study, offering greater understanding of the disease.
whitepaper
ebook: Current and emerging strategies for engineered cell therapies: cancer immunotherapy
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
news
Study uncovers relationship between T cells and CD4
Researchers at the University of Arizona Health Sciences found that CD4 plays an active role in regulating T-cell receptor signalling.
news
Cellistic and Celyad Oncology announce GMP cell therapy manufacturing operations transaction
Cellistic has agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for €6 million.
news
Blocking trogocytosis improves ability of CAR T-cell therapy to treat cancer in mice
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.
news
Combining immunotherapy and virotherapy shows promise for treatment-resistant cancers
The study describes how oncolytic virotherapy can work with existing immunotherapy techniques, boosting the immune capacity to effectively target and destroy cancer cells.
news
Researchers halt the growth of multiple myeloma in mice
Scientists from Stanford University have been able to halt the growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3.
news
Research shows that EBAG9 leads to strengthened immune response to cancer
The scientists say that shutting down the EBAG9 gene allows the body to destroy tumour cells earlier and more radically.
news
Discovered receptor that could alleviate the need for chemotherapy
Researchers have shown that a synthetic IL-9 receptor allows T cells to fight against cancer without the need for chemotherapy or radiation.
news
Global team aims to bring next generation CAR T-cell therapies to children with solid tumours
The Mark Foundation for Cancer Research awards ~$12 million to Cancer Grand Challenges Team to develop new immunotherapies for childhood solid tumours.
whitepaper
Application note: Advancing CAR T-cell therapy with CTS TrueCut Cas9 Protein
Read this free application note where we look at the CTS TrueCut Cas9 Protein, from its detailed quality specifications to its performance in primary T cells.
news
Immunity boosting treatment enhances CAR T-cell therapy for blood cancers
A new study in mice has shown blood cancer treatment with protein interleukin-7 revs up T-cell immunotherapy.
